AR087757A1 - Inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7, sus composiciones farmaceuticas y sus aplicaciones terapeuticas - Google Patents
Inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7, sus composiciones farmaceuticas y sus aplicaciones terapeuticasInfo
- Publication number
- AR087757A1 AR087757A1 ARP120103228A ARP120103228A AR087757A1 AR 087757 A1 AR087757 A1 AR 087757A1 AR P120103228 A ARP120103228 A AR P120103228A AR P120103228 A ARP120103228 A AR P120103228A AR 087757 A1 AR087757 A1 AR 087757A1
- Authority
- AR
- Argentina
- Prior art keywords
- nrr
- alkylene
- branched
- linear
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composición farmacéutica y proceso de preparación. Reivindicación 1: Compuesto de la fórmula (1), en el cual R¹, cada cual es idéntico o distinto, se escoge del grupo que consta de halógeno, R, OR, NRR, CN, CF₃, C(O)R, C(O)OR, C(O)NRR, NO₂, alquileno C₁₋₆-OR, alquileno C₁₋₆-NRR, alquileno C₁₋₆-CO₂R, alquileno C₁₋₆-C(O)NRR, -O-alquileno C₁₋₆-CO₂R, -O-alquileno C₁₋₆-C(O)NRR, CO₂-alquileno C₁₋₆-OR, CO₂-alquileno C₁₋₆-NRR, C(O)NH-alquileno C₁₋₆-OR, C(O)NH-alquileno C₁₋₆-NRR, OCF₃, SO₂R, SO₃H, SO₂NRR, NHSO₂R, R¹⁰CºCR¹¹, (R¹⁰)(R¹¹)C=C(R¹¹)₂, alquileno C₁₋₆-C(O)R, NHC(O)R, ó alquilo C₁₋₆, interrumpido por al menos un heteroátomo, escogido de preferencia de entre O, N o S, de preferencia O; L¹ es alquileno C₁₋₆ linear o ramificado sustituido optativamente por uno o más de =O, CN, C(O)R, C(O)OR o C(O)NRR, o bien CH₂-alquileno C₁₋₆ linear o ramificado, en el cual el alquileno C₁₋₆ posterior es sustituido optativamente por uno o más de halógeno, OR, NRR o CF₃; q es 0, 1, 2, 3 ó 4; X es CR⁷; R⁷ es OR, halógeno, alquilo C₁₋₆-OR linear o ramificado, C(O)OR, C(O)NRR, CN, OR⁹, NRR ó SR; n es 0, 1 ó 2; p es 1, 2 ó 3; R³, R⁴, R⁸ y R⁸, cada cual es idéntico o distinto, son escogidos del grupo que consta de H, alquilo C₁₋₆ linear o ramificado, halógeno, OH, -O-alquilo C₁₋₆, NRR, CN, CF₃, OR, C(O)R, C(O)OR o C(O)NRR; A es escogido del grupo que consta de: -C(O)-; -C(O)NH-; -SO₂-; o -SO₂N-; L² es alquileno C₁₋₆-O linear o ramificado o un alquileno C₁₋₆ linear o ramificado, interrumpido optativamente por al menos un heteroátomo escogido de entre O, NR o S y/o sustituido optativamente por: R, OR, NRR, alquilo C₁₋₆-OR alquilo C₁₋₆-NRR, OC(O)R, NHC(O)R, NHC(O)NRR, CN, C(=NH)NHOR; R⁶ es escogido del grupo que consta de arilo, heteroarilo, cicloalquilo, heterociclo, H, en el cual el arilo, heteroarilo, cicloalquilo o heterociclo es mono o policíclico y es sustituido optativamente por uno o más de alquilo C₁₋₆ linear o ramificado, halógeno, NRR, CN, CF₃, OR, =O, C(O)R, C(O)OR, NHC(O)R, OC(O)R, alquenileno C₂₋₆ linear o ramificado o CONRR; cada R y R, ya sea idéntico o distinto, es escogido de manera independiente, de entre H, alquilo C₁₋₆ linear o ramificado, cicloalquilo, arilo, heterociclo aromático o no aromático o -alquilo C₁₋₆-arilo linear o ramificado, o -alquilo C₁₋₆-heterociclo linear o ramificado, en el cual el heterociclo es aromático o no aromático; sustituido optativamente o no por OH, CO₂H, C(O)NH₂, NH₂; R⁹ es escogido del grupo que consta de -C(O)R, -C(O)NHR, -C(O)OR, -C(O)CH₂-NRR, -C(O)-CH₂-CH₂-CO₂R, -C(O)-CH₂-SO₃H, -C(O)-(C₅H₄N), -PO₃H₂, o su forma ionizada; R¹⁰ es escogido de manera independiente de entre un enlace, un alquilo C₁₋₆ linear o ramificado; R¹¹ es escogido de manera independiente de entre un átomo de hidrógeno, un alquilo C₁₋₆ linear o ramificado o un arilo, siendo el alquilo o arilo optativamente sustituido por OH, NH₂, C(O)OH o C(O)NH; o sus sales farmacéuticamente aceptables, o sus isómeros ópticos, racematos, diastereoisómeros, enantiómeros o tautómeros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306096A EP2565186A1 (en) | 2011-09-02 | 2011-09-02 | Selective and reversible inhibitors of ubiquitin specific protease 7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087757A1 true AR087757A1 (es) | 2014-04-16 |
Family
ID=46750347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103228A AR087757A1 (es) | 2011-09-02 | 2012-08-31 | Inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7, sus composiciones farmaceuticas y sus aplicaciones terapeuticas |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9546150B2 (es) |
| EP (2) | EP2565186A1 (es) |
| JP (1) | JP6059228B2 (es) |
| KR (1) | KR20140085430A (es) |
| CN (1) | CN103930415B (es) |
| AR (1) | AR087757A1 (es) |
| AU (1) | AU2012300944B2 (es) |
| BR (1) | BR112014004649A2 (es) |
| CA (1) | CA2847017A1 (es) |
| CL (1) | CL2014000511A1 (es) |
| DK (1) | DK2751092T3 (es) |
| ES (1) | ES2594603T3 (es) |
| HU (1) | HUE029418T2 (es) |
| IL (1) | IL231203A (es) |
| LT (1) | LT2751092T (es) |
| MA (1) | MA35361B1 (es) |
| MX (1) | MX340500B (es) |
| PL (1) | PL2751092T3 (es) |
| PT (1) | PT2751092T (es) |
| RU (1) | RU2622640C2 (es) |
| SG (1) | SG11201400205QA (es) |
| SI (1) | SI2751092T1 (es) |
| TN (1) | TN2014000079A1 (es) |
| WO (1) | WO2013030218A1 (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| JP2016504365A (ja) | 2012-12-28 | 2016-02-12 | アメリカ合衆国 | Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用 |
| CN105327350A (zh) * | 2014-07-23 | 2016-02-17 | 中国科学院上海巴斯德研究所 | 泛素化途径相关因子在调控辅助性t细胞功能中的应用 |
| MA41291A (fr) * | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| TWI698436B (zh) * | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| WO2016126929A1 (en) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| US9938300B2 (en) | 2015-02-05 | 2018-04-10 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| EP3253738A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
| CN105251020B (zh) * | 2015-09-29 | 2018-10-09 | 武汉大学 | 泛素特异性蛋白酶4（usp4）在治疗心肌肥厚中的功能及应用 |
| GB201522267D0 (en) * | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) * | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| FR3052451B1 (fr) * | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | Nouveaux derives de piperidinyle hetero(aryl)-substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3061177B1 (fr) * | 2016-12-28 | 2019-09-27 | Les Laboratoires Servier | Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR3052452B1 (fr) * | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CU20180146A7 (es) * | 2016-06-10 | 2019-07-04 | Servier Lab | Compuestos derivados de (piperidin-1-ilo)(piperidin-4-ilo) sustituidos con hetero(arilo), un proceso para su preparación y composiciones farmacéuticas que los contienen |
| EP3481803B1 (en) | 2016-07-08 | 2020-09-02 | Mayo Foundation for Medical Education and Research | Methods and materials for treating cancer |
| GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| US11446315B2 (en) * | 2016-11-03 | 2022-09-20 | Pf Argentum Ip Holdings Llc | Enhancement of CD47 blockade therapy by proteasome inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| EP3642196B1 (en) | 2017-06-20 | 2022-08-17 | Mission Therapeutics Limited | Substituted cyanopyrrolidines with activity as dub inhibitors |
| WO2019067503A1 (en) * | 2017-09-26 | 2019-04-04 | Dana-Farber Cancer Institute, Inc. | NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
| WO2020086595A1 (en) * | 2018-10-22 | 2020-04-30 | Dana-Farber Cancer Institute, Inc. | Usp7 inhibition |
| EP3890829A1 (en) * | 2018-12-06 | 2021-10-13 | Almac Discovery Limited | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) |
| US20220125760A1 (en) | 2019-02-14 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of usp7 inhibitors for the treatment of acute myeloid leukemia (aml) |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| CA3146715A1 (en) * | 2019-07-15 | 2021-01-21 | Oncoarendi Therapeutics S.A. | Substituted amino triazoles useful as chitinase inhibitors |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| CN113087718B (zh) * | 2020-01-09 | 2024-02-09 | 四川科伦博泰生物医药股份有限公司 | 噻吩并嘧啶酮类化合物及其医药应用 |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| CA3167473A1 (en) * | 2020-02-28 | 2021-09-02 | Immunologik Gmbh | Inhibitors of human deubiquitinases for the treatment of coronaviral infections |
| CA3171349A1 (en) | 2020-04-08 | 2021-10-14 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| US20210369665A1 (en) * | 2020-05-26 | 2021-12-02 | Lowell Therapeutics, Inc. | Methods of treating viral infection using protease inhibitors |
| BR112022020644A2 (pt) | 2020-05-28 | 2022-12-06 | Mission Therapeutics Ltd | Derivados de n-(1-ciano-pirrolidin-3-il)-5-(3-(trifluorometil)fenil) oxazol-2-carboxamida e os correspondentes derivados de oxadiazol como inibidores de usp30 para o tratamento de disfunção mitocondrial |
| JP2023529570A (ja) | 2020-06-04 | 2023-07-11 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン |
| CN115836073B (zh) | 2020-06-08 | 2024-08-27 | 特殊治疗有限公司 | 用于治疗线粒体功能障碍、癌症和纤维化的作为usp30抑制剂的1-(5-(2-氰基吡啶-4-基)噁唑-2-羰基)-4-甲基六氢吡咯并[3,4-b]吡咯-5(1h)-甲腈 |
| CN112047933B (zh) * | 2020-10-15 | 2022-06-14 | 郑州大学 | 喹唑啉酮类usp7抑制剂及其制备方法和应用 |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| EP4441044A1 (en) | 2021-12-01 | 2024-10-09 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| GB202200753D0 (en) | 2022-01-21 | 2022-03-09 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2796417A (en) * | 1952-04-03 | 1957-06-18 | American Cyanamid Co | Quinazolone compounds and methods of making the same |
| US3073826A (en) * | 1960-10-20 | 1963-01-15 | Mead Johnson & Co | 3-pyrrolidylmethyl-4-quinazolones |
| WO1993012795A1 (en) * | 1985-08-30 | 1993-07-08 | Glazer Edward A | Quinazolin-4(3h)-one derivatives as anticoccidial agents |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US7842522B2 (en) | 2001-10-19 | 2010-11-30 | Applied Nanotech Holdings, Inc. | Well formation |
| US7569578B2 (en) * | 2003-12-05 | 2009-08-04 | Bristol-Meyers Squibb Company | Heterocyclic anti-migraine agents |
| SE0303280D0 (sv) | 2003-12-05 | 2003-12-05 | Astrazeneca Ab | Novel compounds |
| DK1737831T3 (da) * | 2004-04-02 | 2013-08-19 | Prana Biotechnology Ltd | Neurologisk aktive forbindelser |
| SE0401656D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
| WO2006012577A2 (en) * | 2004-07-22 | 2006-02-02 | Bayer Pharmaceuticals Corporation | Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake |
| JP2008511599A (ja) * | 2004-08-31 | 2008-04-17 | アストラゼネカ アクチボラグ | キナゾリノン誘導体およびＢ−Ｒａｆ阻害薬としてのそれらの使用 |
| WO2006072048A2 (en) | 2004-12-30 | 2006-07-06 | The Trustees Of Princeton University | Compositions and methods for identifying modulators of hausp |
| US7709516B2 (en) | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
| DE602005010421D1 (de) | 2005-08-05 | 2008-11-27 | Hybrigenics Sa | Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen |
| ATE453634T1 (de) | 2005-09-06 | 2010-01-15 | Smithkline Beecham Corp | Regioselektives verfahren zur zubereitung von benzimidazol-thiophenen |
| US8163760B2 (en) | 2006-06-22 | 2012-04-24 | Prana Biotechnology Limited | Use of pyridopyrimidine compounds in the treatment of gliomas |
| US20080188498A1 (en) * | 2007-02-05 | 2008-08-07 | Radix Pharmaceuticals, Inc. | Pyridopyrimidinone compounds with antimalarial activity |
| WO2010019210A2 (en) * | 2008-08-11 | 2010-02-18 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
| US8470819B2 (en) | 2008-11-03 | 2013-06-25 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
| US20110177105A1 (en) | 2010-01-15 | 2011-07-21 | Roman Lopez | Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications |
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
-
2011
- 2011-09-02 EP EP11306096A patent/EP2565186A1/en not_active Withdrawn
-
2012
- 2012-08-29 ES ES12751080.8T patent/ES2594603T3/es active Active
- 2012-08-29 DK DK12751080.8T patent/DK2751092T3/en active
- 2012-08-29 LT LTEP12751080.8T patent/LT2751092T/lt unknown
- 2012-08-29 CA CA2847017A patent/CA2847017A1/en not_active Abandoned
- 2012-08-29 HU HUE12751080A patent/HUE029418T2/en unknown
- 2012-08-29 US US14/241,923 patent/US9546150B2/en active Active
- 2012-08-29 JP JP2014527641A patent/JP6059228B2/ja not_active Expired - Fee Related
- 2012-08-29 KR KR1020147007456A patent/KR20140085430A/ko not_active Application Discontinuation
- 2012-08-29 AU AU2012300944A patent/AU2012300944B2/en not_active Ceased
- 2012-08-29 PT PT127510808T patent/PT2751092T/pt unknown
- 2012-08-29 BR BR112014004649A patent/BR112014004649A2/pt not_active Application Discontinuation
- 2012-08-29 RU RU2014112692A patent/RU2622640C2/ru not_active IP Right Cessation
- 2012-08-29 PL PL12751080T patent/PL2751092T3/pl unknown
- 2012-08-29 WO PCT/EP2012/066741 patent/WO2013030218A1/en active Application Filing
- 2012-08-29 SG SG11201400205QA patent/SG11201400205QA/en unknown
- 2012-08-29 SI SI201230714A patent/SI2751092T1/sl unknown
- 2012-08-29 EP EP12751080.8A patent/EP2751092B1/en active Active
- 2012-08-29 MX MX2014002489A patent/MX340500B/es active IP Right Grant
- 2012-08-29 CN CN201280054148.2A patent/CN103930415B/zh not_active Expired - Fee Related
- 2012-08-31 AR ARP120103228A patent/AR087757A1/es not_active Application Discontinuation
-
2014
- 2014-02-21 TN TNP2014000079A patent/TN2014000079A1/en unknown
- 2014-02-25 MA MA36781A patent/MA35361B1/fr unknown
- 2014-02-27 IL IL231203A patent/IL231203A/en active IP Right Grant
- 2014-02-28 CL CL2014000511A patent/CL2014000511A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087757A1 (es) | Inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7, sus composiciones farmaceuticas y sus aplicaciones terapeuticas | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| EA201000805A1 (ru) | Бис-(сульфониламино)производные в терапии 066 | |
| AR091023A1 (es) | Inhibidores del nampt | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| CU23706B7 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| AR090590A1 (es) | COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA | |
| AR088352A1 (es) | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| AR090292A1 (es) | Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR050941A1 (es) | SERINAMIDAS SUSTITUIDAS POR BENZOILO, PROCESOS PARA SU PREPARACION, INTERMEDIARIOS PARA SU SINTESIS, USO DE LAS MISMAS EN LA FABRICACIoN DE PRODUCTOS FITOSANITARIOS Y PROCEDIMEITNSO PARA CONTROLAR EL CRECIMIENTO DE PLANTAS INDESEADAS | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR110753A1 (es) | Inhibidores selectivos de jak1 | |
| AR086482A1 (es) | Inhibidores de aldosterona sintasa | |
| AR092205A1 (es) | 4-piridonas sustituidas y su uso como inhibidores de la actividad de elastasa de neutrofilos | |
| AR088246A1 (es) | Derivados de etinilo | |
| AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |